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Background: Diabetic neuropathy is a complication of diabetes mellitus that develops in about 
50% of people with diabetes. Despite its widespread occurrence and devastating effects, this 
complication is still not fully understood, and there is no treatment available to prevent its 
development.
Methods: In this study, immunocytochemistry for activating transcription factor 3, a marker 
for cell injury, was used to investigate the stress response in dorsal root ganglion neurons in 
both in vitro and ex vivo models of diabetic neuropathy.
Results: Our findings showed increased activating transcription factor 3 expression in hyper-
glycemic culture conditions and in dorsal root ganglion neurons isolated from diabetic rats. 
Glial cell line-derived neurotrophic factor, a substance with known neuroprotective properties, 
was able to reduce diabetes mellitus-induced neuronal stress in vitro, while gabapentin and 
carbamazepine, currently used to treat neuropathic pain, showed only limited effects.
Conclusion: Growth factors may have a therapeutic benefit as neurotrophic agents in the 
treatment of diabetic peripheral neuropathy, but gabapentin and carbamazepine have no direct 
protective effect on sensory neurons. This research also indicates that immunocytochemistry 
for activating transcription factor 3 is a valuable tool for evaluation of pharmacological sub-
stances in dorsal root ganglion cultures.
Keywords: diabetic peripheral neuropathy, dorsal root ganglion, activating transcription   factor 3, 
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Introduction
Diabetic peripheral neuropathy is a common chronic complication of diabetes mellitus 
that develops in about 50% of patients affected with type 1 or 2 diabetes.1 This neu-
ropathy is associated with a spectrum of structural changes in the peripheral nervous 
system, including axonal degeneration, paranodal demyelination, and loss of myeli-
nated fibers.2,3 Although the exact pathogenesis of diabetic peripheral neuropathy is 
unknown, results of the Diabetes Control and Complications Trial have indicated that 
hyperglycemia is a key player in the development of the disorder.4,5 In addition to 
hyperglycemia, neurotrophic factor deficiency has received increasing attention as 
being important in the pathology of diabetic peripheral neuropathy. There is evidence 
indicating that the loss of neurotrophic support seen in diabetes mellitus has detrimental 
consequences for the survival and regenerative responses of neurons.6,7
Despite the devastating effects and widespread occurrence of diabetic peripheral 
neuropathy, there are still no treatments available to prevent its development, other 
than the overall control of the diabetic condition itself. Therefore, it is necessary to study Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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the pathological mechanisms underlying diabetic peripheral 
neuropathy to understand better the development of this 
complication and to look for more specific disease-modifying 
treatments.
In this study, adult rat dorsal root ganglion (DRG) neu-
rons were used as an in vitro model to investigate diabetic 
neuropathy. The sensory perikaryons of the peripheral 
  nervous system, which are the target tissues in the pathophys-
iology of diabetic peripheral neuropathy, are located within 
the DRG. When cultured rat DRG neurons are exposed to a 
variety of toxic insults, the neurons undergo morphological 
and biochemical changes which closely mimic toxin-  mediated 
damage in adult animals and humans.8,9 Therefore, these 
cultured DRG neurons provide a robust and relevant in vitro 
model to investigate diabetic neuropathy. Furthermore, DRG 
neurons can be extracted from normal animals and exposed 
in vitro to toxins, and DRG neurons from diabetic animals 
can be evaluated ex vivo. As such, this approach allows us 
to link in vitro analysis to the in vivo events that occur during 
the development of peripheral neuropathy associated with 
diabetes.
The goal of this research was to explore further the role 
of glial cell line-derived neurotrophic factor (GDNF) in 
diabetic peripheral neuropathy and to compare the effects of 
this growth factor with those of gabapentin and carbam-
azepine, both anticonvulsants currently in use to treat neu-
ropathic pain.10,11 GDNF was originally purified as a potent 
neurotrophic factor that enhances the survival of midbrain 
dopaminergic neurons.12 Subsequent studies showed that 
GDNF also supports the survival of other types of neurons, 
including both motor and sensory neurons.13,14 The potent 
neurotrophic effects of GDNF, together with the reduced 
expression and transport of growth factors seen in animal 
models of diabetes, suggest a promising role for GDNF in 
the treatment of diabetic peripheral neuropathy, and this was 
also investigated in this study.
Gabapentin and carbamazepine are only symptomatic 
treatments available for diabetic neuropathy, and are not 
believed to inhibit or reverse the pathological processes 
involved. Both drugs inhibit the excessive neuronal activity 
seen in neuropathic pain. Carbamazepine decreases abnor-
mal electrical impulses in the nerve by blocking sodium 
channels,15 whereas gabapentin is believed to interact with 
the alpha-2 subunit of the calcium channel to inhibit gluta-
mate release.11,16
To evaluate the potential therapeutic effects of GDNF, 
gabapentin, and carbamazepine, the expression of activating 
transcription factor 3 (ATF3) was measured in both in vitro 
and ex vivo models of diabetic neuropathy. ATF3 is a mem-
ber of the activating transcription factor/cAMP response 
  element-binding family of transcription factors and is induced 
by a variety of stress signals in both neuronal and nonneu-
ronal cells.17–20 ATF3 is an immediate early gene, and a 
change in its expression level is among the earliest events 
reported after injury, suggesting a potential role in the stress 
response. This protein can either activate or repress transcrip-
tion, depending on whether it forms homodimers or heterodi-
mers with Jun proteins.17,21 Because several studies have 
demonstrated that ATF3 is induced in sensory and motor 
neurons after peripheral nerve injury, this transcription factor 
has been generally accepted as a marker for neuronal 
stress.20,22–26 However, all previous studies have quantified 
ATF3 expression immunohistologically, and none have used 
this marker to assess neuronal stress in cultured cells. The 
advantage of using cultured DRG neurons for ATF3 quan-
tification instead of using whole DRGs is the ability to add 
different compounds to the cultured neurons, and in this 
way search for pharmacological substances able to reduce 
the stress associated with diabetes mellitus. Therefore, in this 
study we investigated whether immunocytochemistry for 
ATF3 is an effective tool for evaluation of the effects of 
pharmacological substances in DRG cultures.
Experimental procedures
Rat models
Male Sprague-Dawley rats (Harlan Laboratories, Horst, The 
Netherlands) weighing 240–260 g were fed a standard rodent 
diet and had access to water ad libitum. Diabetes was induced 
by a single intraperitoneal injection of streptozotocin (Sigma-
Aldrich, St. Louis, MO) 65 mg/kg after an overnight fast 
(starvation for 20–24 hours). Blood samples for measurement 
of glucose were taken from the tail vein 48 hours after strep-
tozotocin injection. Rats with a blood glucose level above 
500 mg/dL were considered diabetic and used for further 
experiments. Control animals received buffer solution 
instead. All studies were performed in accordance with 
institutional ethical guidelines for the care and use of labora-
tory animals, and the protocols were approved by the Local 
Animal Care Ethics committee.
Paw pressure test
Mechanical hyperalgesia was quantified using an Analgesy-
Meter (Ugo-Basile, Comerio, Italy). Increasing pressure was 
applied using a cone-shaped plunger on the dorsal area of Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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the hind paw. The nociceptive threshold was defined as 
the force at which the rat attempted to withdraw its paw, 
vocalized, or struggled. The cutoff force was set at 250 g.
isolation of DRg neurons
The rats were sacrificed by carbon dioxide inhalation. 
Immediately thereafter, DRG neurons were dissected from 
the spinal column and collected in phosphate-buffered saline 
containing 1 g/L glucose. After isolation, the ganglia were 
enzymatically dissociated by incubation at 37°C for 
45   minutes in medium containing 0.5% collagenase (Roche 
Diagnostics, Mannheim, Germany) followed by 0.25% 
trypsin (Gibco, Paisley, UK) in phosphate-buffered saline 
for 30 minutes. The ganglia were then collected in   Dulbecco’s 
modified Eagle’s medium (Gibco) enriched with fetal calf 
serum, nonessential amino acids, sodium bicarbonate, and 
L-  glutamine. The ganglia were mechanically dissociated 
into single cells by titration through flame-constricted 
  Pasteur pipettes of decreasing tip diameter. To purify the 
cultures, the cell suspension was placed in a Petri dish previ-
ously coated with fetal calf serum (HyClone, Carlsbad, CA) 
for 90 minutes at 37°C. The DRG neurons were then 
  collected and plated into 10 µg/mL poly-l-lysine-coated 
96-well plates.
DRg cultures and treatment
DRG neurons were cultured in Neurobasal medium (Gibco) 
supplemented with B27 supplement (Gibco). This commer-
cially available medium contains 30 mM glucose. DRG 
neurons were cultured for at least 24 hours in medium con-
taining the indicated compounds. A GDNF concentration in 
the 0.1–10.0 ng/mL range was used because previous studies 
had shown these doses to be effective.27,28 Lower doses were 
not effective, and higher doses showed aberrant stimulation 
(data not shown).
Clinical trials have shown that plasma concentrations 
of 2–11 µg/mL (corresponding to 23–64 µM) for gabap-
entin and 4–16 µg/mL (corresponding with 17–68 µM) for 
carbamazepine are required to produce a therapeutic 
effect.16,29 In this study, DRG neurons were treated for 
24 hours with concentrations of gabapentin and carbam-
azepine in this therapeutic range (10 µM and 100 µM, 
respectively). To ensure that gabapentin and c  arbamazepine 
had no effect on ATF3 expression, and because an in vitro 
model was used, higher concentrations of these anticon-
vulsant drugs were also tested (200 µM and 250 µM, 
respectively).
immunocytochemistry
DRG neurons were fixed for 10 minutes using 0.5% Triton 
X100 (Sigma) and 0.5% glutaraldehyde (Fluka Chemie, 
Buchs, Switzerland) in PHEM buffer (60 mM PIPES, 10 mM 
EGTA, and 2 mM MgCl2, pH 6.0). The cells were washed in 
PHEM before addition of 0.5% Triton X100 alone for 
30   minutes. The cells were again washed with PHEM buffer, 
and then 1 mg/mL NaBH4 (Sigma-Aldrich Chemie, Munich, 
Germany) dissolved in PHEM buffer was added for 
10   minutes. This was followed by a wash in PHEM buffer. 
Prior to addition of primary antibodies, the cells were incu-
bated for 30 minutes in phosphate-buffered saline/bovine 
serum albumin 0.1% (Sigma) buffer containing 5% normal 
goat serum (Sigma). The cells were dual-labeled using a 
polyclonal anti-ATF3 antibody (1:800 dilution in phosphate-
buffered saline/bovine serum albumin; Santa Cruz Biotech-
nology, Santa Cruz, CA) as a neuronal stress marker and the 
monoclonal antineurofilament antibody, SMI32 (1:1000 dilu-
tion in phosphate-buffered saline/bovine serum albumin; 
Sternberger Monoclonals Inc, Baltimore, MD) as a neuronal 
marker. Following overnight incubation at room temperature, 
the cells were washed and incubated with the secondary anti-
bodies, Alexa Fluor 555 goat antirabbit IgG (Invitrogen, 
Carlsbad, CA) and Alexa Fluor 488 goat antimouse IgG 
(Invitrogen). Then the cells were washed with phosphate-
buffered saline/bovine serum albumin, and DAPI (4′,6-
diamidino-2-phenylindole; Sigma) was added for five minutes 
as a nuclear counterstain. After washing, the percentage of 
ATF3-positive neurons was determined in each specific culture 
condition using fluorescence microscopy. Only SMI32- 
positive cells were considered, and irrespective of their size.
Quantitative RT-PcR
The RNeasy kit (Qiagen, Hilden, Germany) was used to extract 
RNA from whole DRGs at the L4, L5, and L6 levels. Approxi-
mately 1 µg of RNA was transcribed to cDNA using the 
QuantiTect reverse transcription kit (Qiagen). Gene expression 
was analyzed by the 7500 Fast real-time polymerase chain 
reaction (RT-PCR) system (Applied Biosystems, Foster City, 
CA) and normalized to ß-actin expression levels.
experiments performed
Determination of optimal glucose levels  
in control cultures
DRGs (from all levels, ie, cervical, thoracic, and lumbar) 
were isolated from control rats and cultured for 24, 48, or 
72 hours in medium containing either 10 mM or 30 mM Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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glucose. The percentage of ATF3-positive neurons was 
determined for each condition (n = 6 wells/3 rats, with at 
least 100 neurons quantified in every well).
ATF3 induction in DRg cultures exposed to 
hyperglycemic conditions
DRG neurons (from all spinal levels) isolated from control 
rats were exposed to different glucose levels for 24 hours and 
labeled for ATF3. The percentage of ATF3-positive neurons 
was determined for each condition (n = 6 wells/3 rats).
Time course of ATF3 expression in DRg cultures  
from diabetic rats
Rats were treated with streptozocin, and DRG neurons from 
all spinal levels were isolated and placed in identical culture 
conditions at the indicated time points. After 24 hours, the 
cells were fixed and processed for ATF3 quantification 
(n = 18 wells from 3 rats/time point).
RT-PcR for ATF3, c-jun, and c-fos in lumbar  
DRgs from diabetic rats
Whole DRGs from levels L4, L5, and L6 were dissected 
from diabetic and control rats and immediately frozen. 
RNA extraction, cDNA preparation, and quantitative RT-
PCR analysis for ATF3, c-jun, and c-fos were conducted 
(n = 6 rats).
effect of gDnF, gabapentin, and carbamazepine  
on acute hyperglycemia-induced ATF3 expression  
in DRg cultures
DRGs from all levels were isolated from control animals. 
After one day in culture, the cells were treated for four hours 
with the compounds at the indicated concentrations. The 
concentration of glucose in the medium was increased to 
60 mM, and 24 hours later the cultures were processed for 
ATF3 quantification (n = 6 wells/3 rats). The percentage of 
positive neurons was determined and the relative increase 
calculated for each condition when compared with normal 
culture conditions.
effect of gDnF, gabapentin, and carbamazepine  
ex vivo on ATF3 expression in DRg cultures  
from diabetic rats
DRGs from all levels were isolated from diabetic animals 
7–13 weeks after streptozocin injection. Immediately after 
isolation, the cells were treated with the compounds at the 
indicated concentrations, and 24 hours later, the cultures 
were processed for ATF3 quantification. The percentage of 
ATF3-positive neurons was determined, and the relative 
changes calculated for each condition when compared with 
compound-treated cultures from nondiabetic control rats 
(n = 6 wells/3 rats).
effect of in vivo gDnF on ATF3 expression  
in DRg cultures from diabetic rats
After 10 weeks of being in a diabetic state, the rats received 
a subplantar injection of GDNF 1 mg/mL or phosphate-
buffered saline in the left paw for three consecutive days. 
L4, L5, and L6 DRG neurons from the left side were then 
isolated. After 24 hours in culture, the cells were fixed and 
processed for ATF3 quantification (n = 6 wells/3 rats).
effect of gDnF treatment on diabetes-induced  
pain hypersensitivity in vivo
Two-week diabetic rats received a subplantar injection of 
GDNF 1 mg/mL or phosphate-buffered saline in the left paw 
for three consecutive days. The paw pressure test was used 
to investigate mechanical hyperalgesia. The animals were 
followed up from one day before until four weeks after 
streptozocin injection (n = 10 rats/group).
statistical analysis
The results are shown as the mean ± standard error of the 
mean. To calculate the significant difference between 
two groups, a Student’s t-test was used. To test whether 
the mean values were significantly different between 
more than two groups, we used a one-way analysis of vari-
ance test,   followed by a post hoc Holm–Sidak multiple 
comparisons test. A P value of ,0.05 was set as the level 
of statistical significance.
Results
Determination of the optimal glucose 
levels in control cultures
We evaluated two commonly used concentrations of glucose 
in the culture medium to determine the concentration of 
glucose required for optimal growth of DRG neurons. Several 
studies of adult rat DRG cultures have used 10 mM glucose 
in control conditions.30,31 Others state that optimal DRG 
survival and neurite growth require 25–30 mM basal 
glucose9,32 because sensory neurons have high metabolic 
requirements. This higher concentration of glucose is 
often used in embryonic DRG cultures. To compare both 
conditions, DRG neurons were isolated from rats and cultured Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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in Neurobasal medium containing either 10 mM or 30 mM 
glucose. After 24, 48, or 72 hours in culture, the neurons 
were fixed and used for ATF3 quantification (Figure 1). There 
was no significant difference in ATF3 expression in DRG 
neurons cultured in medium containing 10 or 30 mM glucose 
for the three time points (Figure 2). However, we did see a 
slightly higher percentage of ATF3-positive neurons in 
medium containing 10 mM of glucose after 48 and 72 hours 
in culture, indicating that 30 mM glucose might be able to 
meet the high metabolic requirements of DRG neurons better 
after a longer culture period. Because most of our subsequent 
work required a culture period of 48 hours, we used medium 
containing 30 mM glucose for all experiments.
induction of ATF3 in DRg cultures 
exposed to hyperglycemic conditions
To evaluate the effect of high glucose concentrations, cul-
tured DRG neurons were exposed for 24 hours to hypergly-
cemic culture conditions. The cells were harvested in culture 
medium containing a total glucose concentration of 
30–110 mM. Exposure to the higher glucose concentrations 
induced an increase in the number of ATF3-positive cells 
when compared with control cultures (30 mM glucose), with 
significant changes from 60 mM glucose onwards (Figure 3). 
A concentration of 110 mM glucose showed no significant 
increase in ATF3 expression. This underestimation of cellular 
stress is most likely due to cell loss.
ATF3 expression in DRg cultures from 
diabetic rats
To investigate whether there is a higher level of neuronal stress 
in diabetic conditions in vivo and to document the time course 
of this process, DRG neurons were isolated from rats at   different 
time points after streptozotocin injection. ATF3 expression was 
quantified after a one-day culture period. The results show 
a time-dependent increase in neuronal stress response after 
streptozocin injection (Figure 4). One week after streptozocin 
treatment, a slight but not statistically significant increase in 
ATF3 expression was observed compared with DRG neurons 
isolated from age-matched control rats. The ATF3 level was 
significantly increased four weeks after streptozocin injection 
and rose further until week 16. At this point, there was a 
three-fold increase in ATF3-positive neurons.
To confirm that the increased ATF3 expression seen in 
DRG neurons isolated from diabetic rats was not due to a 
Neurofilament Composed image  ATF3
Figure 1 example of dorsal root ganglion neurons stained for ATF3 (red) and 
neurofilament (green). Dorsal root ganglion neurons were isolated from control 
rats and plated in 96-well plates.  After one day in culture, the cells were incubated 
in 60 mM glucose for 24 hours and stained for ATF3 and neurofilament.
Abbreviation: ATF3, activating transcription factor 3.
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%
 
A
T
F
3
-
p
o
s
i
t
i
v
e
 
D
R
G
 
n
e
u
r
o
n
s
0
10
20
30
40
50
10 mM glucose
30 mM glucose
24 h 72 h 48 h  
Figure 2 Determination of optimal glucose concentration in control conditions. Dorsal 
root ganglion neurons were cultured in medium containing 10 or 30 mM glucose for 
24, 48, and 72 hours. No significant differences were observed in ATF3 expression. 
Note: shown is the mean of six wells from three rats ± standard error of the mean. 
Abbreviations: ATF3, activating transcription factor 3; DRg, dorsal root ganglion.
Figure 3 neuronal stress in DRg neurons in hyperglycemic culture conditions. 
DRg neurons were treated for 24 hours with different concentrations of glucose. An 
increase in ATF3 expression was seen with doses between 60 and 80 mM glucose. 
Note: shown is the mean of six wells from three rats ± standard error of the 
mean (*P , 0.05). 
Abbreviations: ATF3, activating transcription factor 3; DRg, dorsal root ganglion.
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higher vulnerability of diabetic neurons to the isolation 
  procedure, we did an RT-PCR analysis of whole DRG neurons 
from four-week diabetic rats (ie, four weeks after streptozocin 
injection) and compared the results with those from age-
matched control animals. DRG neurons from levels L4, L5, 
and L6 were dissected from the spinal column and immediately 
frozen. RNA extraction, cDNA preparation, and RT-PCR 
analysis were carried out for ATF3, as well as for other stress-
related genes, ie, c-jun and c-fos. The results show an increase 
in ATF3, c-jun, and c-fos in whole DRG neurons from diabetic 
rats when compared with control animals, which was signifi-
cant for ATF3 and c-jun (Figure 5). This indicates that there 
was indeed higher neuronal stress in DRG neurons from dia-
betic rats, and that this increase was not due to a higher vulner-
ability to the isolation procedure. The level of c-jun in control 
animals (14.44 ± 0.84) was four times higher when compared 
with ATF3 expression in control rats (3.40 ± 0.31), making 
ATF3 a more specific marker for stress.
Pharmacological modulation of acute 
hyperglycemia-induced ATF3  
expression in vitro
DRG neurons isolated from nondiabetic rats were pretreated 
with different concentrations of GDNF (0.1–10.0 ng/mL), 
gabapentin (10–250 µM), and carbamazepine (10–250 µM). 
After four hours, hyperglycemia was induced by incubating 
the cells in 60 mM glucose for 24 hours. The percentage of 
ATF3-positive neurons increased from 27.2 ± 2.57 in controls 
to 59.6 ± 4.92 in hyperglycemic cultures, ie, a 126% relative 
increase in ATF3-positive DRG neurons was observed. GDNF 
significantly blocked the increased ATF3 levels at doses of 
1.0–0.1 ng/mL (Figure 6), indicating that GDNF is able to 
limit glucose-induced neuronal stress levels. DRG neurons 
exposed to hyperglycemia and pretreated with gabapentin or 
carbamazepine for four hours did not show a significant reduc-
tion in the percentage of ATF3-positive DRG neurons.
Pharmacological modulation of diabetes-
induced ATF3 expression ex vivo 
Next we evaluated the effect of GDNF, gabapentin, and car-
bamazepine ex vivo on the stress response of DRG   neurons 
in eight-week diabetic rats and controls. DRG neurons were 
isolated and treated immediately with different   concentrations 
of the respective substances for 24 hours. The percentage of 
ATF3-positive DRG neurons increased from 29.9 ± 2.5 in 
controls to 54.7 ± 0.9 in diabetic rats, ie, a 75% relative increase 
in ATF3 was observed. Treating DRG neurons with gabapentin 
or carbamazepine (100–250 µM) did not reduce the percentage 
of ATF3-positive DRG neurons, whereas GDNF significantly 
reduced diabetes-induced ATF3 expression at doses of 10 and 
1 ng/mL (Figure 7). This indicates that in vitro treatment with 
GDNF can effectively diminish diabetes-associated neuronal 
stress, whereas gabapentin and carbamazepine are not effica-
cious in reducing ATF3 levels of streptozocin-isolated DRG 
neurons treated ex vivo.
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Figure  4  neuronal  stress  at  different  time  points  after  streptozocin  injection. 
Dorsal root ganglion neurons were isolated before streptozocin injection and at 
weeks 1, 2, 4, 8, 12, 16, and 24 after streptozocin treatment.  ATF3 expression is 
increased in dorsal root ganglion cultures isolated from 4–24-week diabetic rats. 
Note: shown is the mean percentage of six wells from three rats ± standard error 
of the mean (*P , 0.05). 
Abbreviations: ATF3, activating transcription factor 3; DRg, dorsal root ganglion; 
sTZ, streptozocin.
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Figure  5  Real-time  polymerase  chain  reaction  analysis  of  dorsal  root  ganglion 
cultures from L4, L5, and L6 for the genes ATF3, c-jun, and c-fos. Dorsal root ganglion 
neurons were dissected from the spinal column of four-week diabetic rats and used 
for real-time polymerase chain reaction analysis. There is an increase in the ATF3, 
c-jun, and c-fos genes in whole dorsal root ganglion neurons isolated from diabetic 
rats, which is significant for ATF3 and c-jun. 
Note: shown is the mean number of copies/10 × 3 copies relative to control values 
bAct of three rats (*P , 0.05).
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effect of in vivo gDnF treatment on the 
diabetes-induced ATF3 expression
To confirm further the protective effect of GDNF on diabetes-
induced neuronal stress, diabetic rats were treated with GDNF 
in vivo before DRG isolation and ATF3 sampling.   Ten-week-old 
diabetic rats received subplantar injections of either GDNF 1 mg/
mL or phosphate-buffered saline into the left hind paw for three 
consecutive days. DRGs from L4, L5, and L6 on the left side 
were then dissected from the spinal column, cultured for 
24 hours, and used for ATF3   quantification. Diabetic rats treated 
with phosphate-buffered saline showed significantly higher ATF3 
levels in DRG   cultures when compared with   nondiabetic control 
rats, whereas GDNF treatment significantly reduced ATF3 
expression in DRG cultures from diabetic animals (Figure 8).
effect of gDnF on pain hypersensitivity 
in diabetic rats in vivo
Because GDNF treatment was able to block hyperglycemia- 
induced and diabetes-induced ATF3 expression in DRG 
neurons, we investigated whether this protective effect also 
occurs in diabetes-induced pain hypersensitivity in vivo. 
Diabetic rats received subplantar injections of GDNF 
1 mg/mL or phosphate-buffered saline in the left hind paw 
on days 17, 18, and 19 after streptozocin injection. The 
paw pressure test was used to investigate mechanical 
hyperalgesia, starting one day before diabetes induction 
and continuing until four weeks after streptozocin   injection. 
A decrease in the withdrawal threshold was observed in 
rats two weeks after streptozocin injection when compared 
with age-matched control animals, indicating pain hyper-
sensitivity in diabetic rats (Figure 9). When the diabetic 
animals were treated with GDNF, a significant increase in 
withdrawal pressure was observed when compared with 
the diabetic controls, being significant from days 2–6 after 
the first GDNF injection. These results indicate a protective 
effect of GDNF on   diabetes- induced pain hypersensitivity, 
thereby further confirming our in vitro results.
Discussion
The present study shows a significant increase in neuronal 
stress in DRG neurons cultured in hyperglycemic conditions, 
starting from a concentration of 60 mM glucose. The effect 
of high glucose concentrations on ATF3 expression in adult 
DRG cultures has not been investigated previously. However, 
earlier studies have investigated cell death in embryonic 
sensory neurons exposed to high glucose concentrations. 
Hyperglycemia (45 mM glucose) has been shown to trigger 
oxidative stress in DRG cultures by increasing the production 
of reactive oxygen species, resulting in apoptosis.9,33,34 
  Russell et al35 further indicated that mitochondria are 
a  ssociated with glucose-induced programmed cell death in 
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Figure  6  effect  of  in  vitro  pretreatment  with  gDnF,  gBP,  and  cBMZ  on 
glucose-induced neuronal stress. DRg neurons were treated for four hours with 
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neurons, and showed that high glucose induces mitochondrial 
swelling and depolarization in sensory neurons. This not only 
leads to generation of reactive oxygen species, but also to 
partial depletion of ATP, an event that is coupled with 
apoptosis.
The effects of hyperglycemia are more difficult to 
investigate in adult sensory neurons. Gumy et al30 and 
Zherebitskaya et al31 were unable to show differences in 
neuronal death and oxidative stress over a four-week period 
in sensory neuron cultures from adult rats exposed to hyper-
glycemia (50–60 mM glucose). Differences in culture 
conditions between embryonic and adult cell cultures may 
play a role and, in particular, the presence of non-neuronal 
cells in the adult cultures may be protective. However, it 
is useful to investigate adult sensory neurons as an in vitro 
model because this is closer to the in vivo situation in ani-
mals and humans. Furthermore, cultured embryonic sensory 
neurons are phenotypically different from adult sensory 
neurons, and are dependent on neurotrophic factor-derived 
support for survival,36 which makes it difficult to study the 
effect of growth factors in this culture model. Quantification 
of ATF3 expression in adult sensory neurons appears to 
be a valuable tool to evaluate cellular dysfunction. ATF3 
is an immediate early gene which is expressed immediately 
after cell injury. Upregulation of ATF3 after axotomy has 
been shown to stimulate axonal outgrowth and cell survival 
in an attempt to rescue the injured neuron.37–39 Because 
ATF3 is expressed before other damage to the cell occurs, 
it is a good early marker to quantify cellular stress.
In diabetic rats, a higher ATF3 expression was observed 
in DRG neurons starting one week after a single streptozotocin 
injection of 65 mg/kg intraperitoneally and reaching signifi-
cance four weeks after streptozocin injection. These results 
correlate with in vivo testing in which streptozocin rapidly 
produced a marked effect. Forty-eight hours after streptozocin 
injection, rats were already hyperglycemic and showed physi-
cal signs of diabetes. Tactile allodynia is evident six days 
after streptozocin injection, and mechanical hyperalgesia 
develops after 9–13 days.40 Histological   investigation of 
DRGs isolated from diabetic rats have also revealed several 
pathological changes four weeks after streptozocin injection. 
Russell et al9 showed condensation of chromatin, shrinkage 
of the nucleus and cell cytoplasm, and ballooned   mitochondria, 
with disruption of the inner cristae structure in DRG neurons, 
all of which are early signs of apoptosis. Srinivasan et al41 
further confirmed these findings by demonstrating apoptosis 
and mitochondrial depolarization in DRG neurons isolated 
from diabetic rats 4–6 weeks after streptozocin   injection. 
The high ATF3 expression and apoptotic changes in DRG 
neurons, together with the altered sensory function in diabetic 
animals, may indicate the onset of diabetic   peripheral 
neuropathy.
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Our findings complement those of Wright et al,42 who 
found a significantly higher level of ATF3 expression in DRG 
neurons of diabetic mice when compared with controls. ATF3 
expression was apparent three weeks after streptozocin 
  injection, while one-week diabetic mice showed no ATF3 
expression. This correlates with our observations, which 
showed a significantly increased ATF3 expression in rat DRG 
cultures starting from four weeks after streptozocin injection. 
Due to the different experimental methods used in our study, 
there was little difference in ATF3 expression seen in the 
DRG neurons from nondiabetic rats. We observed 19.48% 
ATF3-positive neurons in our control rats while Wright et al42 
observed few, if any, ATF3-positive DRG neurons in their 
control mice. Wright et al dissected only L4 and L5 DRGs, 
which were immediately fixed and used for histological 
research. In our study, we used DRG neurons which had been 
cultured for at least 24 hours before fixation and immuno-
cytochemistry. Isolation and culture of DRG neurons is in 
itself a stressful event for these cells, explaining the higher 
ATF3 levels in control cultures.43 In addition to this, a higher 
vulnerability of the DRG neurons from diabetic rats to the 
isolation and culture conditions might also contribute to the 
observed increase in ATF3 expression.
In contrast with Wright et al,42 a study by Dahlin et al44 
concluded that diabetes does not in itself cause an increase 
in ATF3 expression, but it does enhance the expression of 
ATF3 in response to nerve injury. To investigate whether 
the higher ATF3 expression seen in DRG cultures from 
diabetic rats is not just due to a higher vulnerability of the 
neurons to the isolation procedure, we undertook an RT-PCR 
analysis of whole-mounted DRGs for the stress-related genes, 
ATF3, c-jun, and c-fos. Four weeks after streptozocin 
  injection, there was a significantly higher level of ATF3 and 
c-jun seen in whole-mounted L4, L5, and L6 DRG neurons 
isolated from diabetic rats when compared with age-matched 
controls. This confirms the results seen in DRG cultures, 
indicating that diabetes does increase the stress level in 
DRG neurons.
Previous work has shown that growth factors promote 
survival of peripheral neurons and induce neuronal regenera-
tion in in vitro and in vivo models of neurological injury and 
disease. GDNF has attracted considerable attention because 
of its ability to support the survival of dopamine-containing 
neurons which degenerate in Parkinson’s disease, and is 
therefore an attractive agent for the treatment of this disease.12 
GDNF is also a potent survival factor for spinal motor 
neurons, and so could have clinical importance for the 
treatment of amyotrophic lateral sclerosis.13 GDNF has been 
found to hold promise as a potential agent in the treatment 
of diabetic peripheral neuropathy. Akkina et al45 demon-
strated that GDNF administration to diabetic mice reversed 
diabetes-induced deficits in the spinal cord. Furthermore, 
Christianson et al46 reported that GDNF might be effective 
in improving the cutaneous innervation deficits that occur in 
sensory neuropathies. Because of these known neuroprotec-
tive properties, the effect of GDNF on diabetes-induced 
neuronal stress in rat DRG cultures was evaluated in the 
present study. We showed that pretreatment with GDNF 
inhibited the increase in ATF3 expression after exposure of 
DRG neurons to hyperglycemia in vitro. Furthermore, GDNF 
treatment of DRG cultures from diabetic rats ex vivo and 
subplantar injections of GDNF in vivo decreased diabetes-
induced ATF3 levels in DRG neurons.
This study is the first to show the beneficial effect of 
GDNF on the neuronal stress response in conditions of 
in vitro diabetic peripheral neuropathy. Previous studies 
illustrated the effect of GDNF on ATF3 expression after 
nerve injury, but no studies were conducted in models of 
diabetes. Averill et al47 showed that GDNF partially prevents 
the upregulation of ATF3 in DRG neurons after unilateral 
sciatic nerve axotomy in rats. A similar study was conducted 
by Wang et al,48 in which they induced neuronal injury by 
spinal nerve ligation in rats and evaluated the effect of 
GDNF on the injury-induced neuronal damage. Like in the 
present study, the same neuroprotective effects for GDNF 
were found.
Gabapentin and carbamazepine are anticonvulsant drugs 
currently in use for the treatment of neuropathic pain and 
peripheral neuropathies, including diabetic neuropathy. In 
contrast with GDNF, these drugs act only symptomatically. 
Few studies have investigated the effects of gabapentin and 
carbamazepine in DRG cultures, so we compared the effect 
of both these anticonvulsants on neuronal stress with that of 
GDNF. Our experiments show that both gabapentin and 
carbamazepine have limited neuroprotective ability, which 
is in line with their presumed mechanism of action, whereas 
GDNF is able to reduce diabetes-induced neuronal stress.
In summary, our results show increased ATF3 expression 
in DRG neurons in hyperglycemic culture conditions and in 
DRGs isolated from diabetic rats. Inhibition of neuronal 
stress could be important in the development of disease-
modifying therapy for diabetic peripheral neuropathy. 
GDNF, a substance with known neuroprotective properties, 
was able to reduce diabetes-induced neuronal stress, while Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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gabapentin and carbamazepine, currently in use for the 
treatment of neuropathic pain, showed only limited effects.
Conclusion
Overall, we can conclude that growth factors show promise 
as neurotrophic agents in the treatment of diabetic peripheral 
neuropathy, whereas gabapentin and carbamazepine have no 
direct protective effect on sensory neurons. These results 
warrant further research to confirm the disease-modifying 
potential of GDNF in peripheral neuropathy. Furthermore, 
this study indicates that immunocytochemistry for ATF3 
expression is a reliable marker of stress in DRG cultures, and 
allowing pharmacological evaluation of compounds in this 
model.
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